Latest Breaking News On - Rial svra us8051111016 - Page 1 : comparemela.com

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024 48-week placebo-controlled trial is. | May 15, 2023

Pharma gmbMatt paulsSavara incQuarter financial resultsNebulizer systemPrivate securities litigation reform actConsolidated statementsSavara inc stock exchangePress releaseRial svra us8051111016